Robert S Nixon
Biographic Data
| ID | 9063805 |
|---|---|
| NAME | Robert S Nixon |
| GIVEN NAMES | Robert S |
| FAMILY NAME | Nixon |
| SIGNATURE | NIXON R S |
| AFFILIATIONS | University of Washington |
| VERIFIED | No |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 1 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2026 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Phenotypic impacts of treatment-selected mutations in HIV-2 protease on darunavir and lopinavir susceptibility
Compared to HIV-1, HIV-2 infection is characterized by lower viral loads and slower decline in CD4 cells, however the majority of people living with HIV-2 (PLWH2) progress to AIDS and will benefit from antiretroviral therapy. Mutations leading to protease inhibitor (PI) resistance in HIV-2 are poorly characterized, but have important implications for second-line therapy. We evaluated the phenotypic drug susceptibility impacts of HIV-2 protease ch…
No prominent works on this page.
Phenotypic impacts of treatment-selected mutations in HIV-2 protease on darunavir and lopinavir susceptibility
Compared to HIV-1, HIV-2 infection is characterized by lower viral loads and slower decline in CD4 cells, however the majority of people living with HIV-2 (PLWH2) progress to AIDS and will benefit from antiretroviral therapy. Mutations leading to protease inhibitor (PI) resistance in HIV-2 are poorly characterized, but have important implications for second-line therapy. We evaluated the phenotypic drug susceptibility impacts of HIV-2 protease ch…
Darunavir (1 work) · Drug resistance (1 work) · Genotype (1 work) · HIV Research and Treatment (1 work) · HIV/AIDS drug development and treatment (1 work) · HIV/AIDS Research and Interventions (1 work) · Lopinavir (1 work) · Phenotype (1 work) · Protease (1 work) · Protease inhibitor (pharmacology) (1 work)